The Latest Breaking News from Surgalign Holdings

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga · Aug 24, 2022

Here's Why Surgalign Holdings Shares Are Falling Today

Surgalign Holdings Inc (NASDAQ: SRGA) shares are trading lower by 19.73% at $0.15 after the company announced a 1-for-30 reverse stock split. The 1-for-30 reverse stock split will take effect at the opening of trading on the Nasdaq Global Select Market on Tuesday.

Benzinga · May 16, 2022

Recap: Surgalign Holdings Q1 Earnings

Surgalign Holdings (NASDAQ:SRGA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · May 10, 2022